Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 3—March 2005

Research

Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes

Nigel J. Temperton*Comments to Author , Paul K. Chan†, Graham Simmons‡, Maria C. Zambon§, Richard S. Tedder*, Yasuhiro Takeuchi*, and Robin A. Weiss*
Author affiliations: *University College London, London, United Kingdom; †Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special Administrative Region, People’s Republic of China; ‡University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; §Health Protection Agency Central Public Health Laboratory, London, United Kingdom

Main Article

Figure 2

Correlation of neutralizing antibody titers measured by plaque reduction assay with titers measured with pseudotype assay. LV, neutralizing antibody titer by using replication-competent severe acute respiratory syndrome–associated coronavirus (SARS-CoV) (live virus); PV, neutralizing antibody titer by using pseudotype virus; PV90 (filled black diamonds), 90% neutralizing antibody titer by using murine leukemia virus (MLV) (SARS) pseudotype virus; PV50 (open squares), 50% neutralizing antibody ti

Figure 2. . Correlation of neutralizing antibody titers measured by plaque reduction assay with titers measured with pseudotype assay. LV, neutralizing antibody titer by using replication-competent severe acute respiratory syndrome–associated coronavirus (SARS-CoV) (live virus); PV, neutralizing antibody titer by using pseudotype virus; PV90 (filled black diamonds), 90% neutralizing antibody titer by using murine leukemia virus (MLV) (SARS) pseudotype virus; PV50 (open squares), 50% neutralizing antibody titer. Logarithmic trendlines were fitted to the data by using Microsoft Excel 2003 (Microsoft Corp., Redmond, WA, USA). Correlation coefficients for LV versus PV90 and LV versus PV50 are 0.69 and 0.78, respectively.

Main Article

TOP